Asher Bio is applying our cis-targeting platform to make a quantum leap in precisely-targeted immunotherapies.

With cis targeting, we have the potential to broaden the therapeutic window of cytokines and other potent signaling molecules, offering improvements in both efficacy and safety.

Our lead program is AB248, a CD8+ T cell cis-targeted IL-2 immunotherapy. Interleukin 2 (IL-2) is a clinically validated immunotherapy that achieves durable complete responses in difficult to treat cancers, but its use is severely limited due to toxicity. The potent underlying efficacy potential of IL-2 but inherent pleiotropy made it an ideal candidate for cis-targeting.

As a potential best-in-class IL-2-based immunotherapy, we are developing AB248 to address multiple solid tumor indications as monotherapy and in combination with checkpoint inhibitors. Further expansion of AB248 may include applications in cell therapy and in the treatment of certain infectious diseases.

Beyond AB248, Asher Bio is applying our modular toolkit to rapidly develop a pipeline of cis-targeted immunotherapies. To date, preclinical proof-of-concept has been established for three cis-targeted drug programs that include directing two distinct cytokines to two different cell types.

Pipeline Chart

LEARN ABOUT AB248, OUR CD8+ IL-2 THERAPY

Our lead cis-targeted immunotherapy, AB248, selectively activates the IL-2 receptor on CD8+ T cells stimulating proliferation, and has shown highly compelling preclinical efficacy.

AB248

LEARN ABOUT AB821, OUR CD8+ IL-21 THERAPY

AB821 is our CD8+ T cell cis-targeted IL-21 cytokine designed to maximize the function and survival of CD8+ T cells.

AB821

LEARN ABOUT OUR CIS-TARGETED AUGMENTATION OF CELL THERAPIES

A CAR-T cell cis-targeted IL-2 cytokine that specifically activates CAR-Ts, while exhibiting minimal activity on CAR-negative cells.

CAR-T selective IL-2 fusion molecule

 
 

This links to an external website.

Continue